Analysis in endothelial cells of patients with advanced melanoma showed that only 17 out of 43 patients have an increased IDO expression and only 2 of 43 patients were IDO1 and PD-L1 double positive (39) revealing that IDO is not an appropriate target for the majority of melanoma patients. This evidence concerns the gene IDO1 and melanoma.